🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →
S&P 500: 776.34 -0.2% NASDAQ 100: 731.07 -0.1% Dow Jones: 536.80 -0.2%

Arch Venture Management - Q2 2026 13F Filings

AR

Arch Venture Management, LLC

CIK: 0001274403
Address: Illinois Chicago C/O Arch Venture Partners 8755 W. Higgins Rd. #1025
$1.1 B
Portfolio Value
12
Assets Held
Reporting Period: Q2 2026
Filing Status:
Active
Last Updated: 08/14/2026

Portfolio Summary (Q2 2026)

View Full Portfolio Analysis

Top Buys

Q2 2026
1. PBLS Parabilis Medicines
+$175.52 M
2. SPTX Seaport Therapeutics
+$136.6 M
3. BOLD Boundless Bio
+$6.74 M

Top Sells

Q2 2026
1. VIR Vir Biotechnology
−$2.27 M
2. QTTB Q32 Bio
−$2.06 M

Asset Allocation

Stocks/ETFs
+62.50%
$1.1 B 100.00%
Options
$0 0.00%
Debt
$0 0.00%
Other
$0 0.00%

Sector Allocation (Stocks)

Arch Venture Management Q2 2026 Filing Summary

Arch Venture Management, LLC filed its 13F report for Q2 2026 on August 14, 2026. The portfolio totaled 1.1 B reflecting a +62.50% change from the prior quarter, spanning 12 assets. The top 10 holdings comprised 99.3% of the portfolio, with Financials as the largest sector allocation. Quarterly activity included 3 new positions and 1 complete exits.

Report Type

Status

Data Summary

Items:

Total Value:

Actions

Issuer Name Class Value Shares Option Type

FAQs for Arch Venture Management’s Q2 2026 Filing

Arch Venture Management submitted their Form 13F-HR for the Q2 2026 period on 08/14/2026. This was the only submission for the quarter.

In the Q2 2026 filing, Arch Venture Management reported a managed portfolio value of 1.1 B, consisting of 12 individual positions.

This page displays the raw filing documents. To see which stocks Arch Venture Management bought or sold during Q2 2026, please visit Arch Venture Management's Portfolio Analysis page.